ProCE Banner Activity

Key Emerging Treatment Strategies for Patients With EGFR-Mutated Advanced NSCLC

Slideset Download
Download these slides for emerging data and a summary of key ongoing clinical trials evaluating novel combination therapies and antibody–drug conjugates for patients with EGFR-mutated advanced NSCLC in the first-line setting and beyond.

Released: September 30, 2022

Expiration: September 29, 2023

No longer available for credit.

Share

Faculty

Catherine A. Shu

Catherine A. Shu, MD

Associate Professor of Medicine
Department of Hematology/Oncology
Clinical Director
Thoracic Medical Oncology
Columbia University Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Catherine A. Shu, MD

Associate Professor of Medicine
Department of Hematology/Oncology
Clinical Director
Thoracic Medical Oncology
Columbia University Medical Center
New York, New York

Catherine A. Shu, MD: consultant/advisor/speaker: AstraZeneca, Genentech, Janssen, Mirati.